About us
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
Our stories
Everyone has a story about how mental health has affected them or someone they know. Our people bring their stories, and a wide range of backgrounds and skills, to Compass.
Our work
We want to give people living with mental health challenges better options.
News and views
Read our latest news and updates.
Join us
We are united by our commitment to improving mental health.
Our purpose
Watch our purpose video to find out who we are and what defines us.
News and views
Our collective understanding of mental illness is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Find out how we use digital tools, including AI, software and mathematics, to better understand mental illness.
Investors
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
COMP360 psilocybin treatment in TRD
We have completed the largest randomised, controlled, double-blind psilocybin treatment study ever done.
Impact
We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.
About us
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
We conducted an exploratory study of investigational COMP360 psilocybin treatment in combination with SSRI use. The open-label study involved 19 patients taking SSRI therapy alongside 25mg COMP360 psilocybin treatment. The results showed comparable treatment outcomes to those seen in patients in our phase 2b trial, where patients were withdrawn from their SSRI before they received COMP360 psilocybin treatment.
Press release
Dr Guy Goodwin, Chief Medical Officer, Compass Pathways
Watch the video to hear Dr Goodwin talk about the study and what it could mean for future clinical trials using our investigational COMP360 psilocybin treatment.
“This study is an important contribution to our knowledge and has significant implications for clinical research with psychedelics.
Pragmatically, the findings suggest that future clinical trials of psilocybin treatment may be able to include patients who have great difficulty coming off SSRI antidepressants and that, ultimately, such patients could be eligible for any psilocybin treatments that may become approved.”
Dr David Feifel, Professor Emeritus of Psychiatry and Principal Investigator on the trial’s site at Kadima Neuropsychiatry Institute
This website is powered by renewable energy
Subscribe to receive the latest Compass news.
Compass © 2024. All rights reserved. Made by GIG.
The press releases and articles contained in this section are provided for historical purposes only. The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. Compass disavows any obligation to update the information contained in such press releases and articles after the date of their issuance.
Compass does not control and is not responsible for the content on the website you are about to visit. Compass is providing this link as a convenience, and this link does not imply Compass endorsement of any material on the website you are about to visit. Do you wish to continue?
COMP360 psilocybin treatment in TRD with antidepressants – COMPASS Pathways
